Carolina Schinke

High Impact

Associate Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

36 h-index 369 pubs 4,773 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Carolina Schinke's research focuses on plasma cell dyscrasias, including multiple myeloma, its precursors, and related conditions such as amyloid disease and Waldenström's macroglobulinemia. Her work investigates the molecular underpinnings of multiple myeloma, exploring its evolutionary pathways from smoldering stages to relapsed and refractory states. Dr. Schinke also examines the role of the immune microenvironment in disease progression at a single-cell level.

Her recent publications include studies on the molecular makeup of smoldering myeloma, the risk of infections associated with bispecific antibodies in multiple myeloma treatment, and the pivotal results of talquetamab, a GPRC5DxCD3 bispecific antibody, for relapsed/refractory multiple myeloma. She has also contributed to multi-institutional real-world studies on teclistamab and has investigated geographic and racial disparities in access to clinical trials for multiple myeloma therapies. Dr. Schinke is affiliated with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, where she leads a research group and collaborates with several colleagues, including Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, and Samer Al Hadidi.

Research Overview

Dr. Carolina Schinke is an Associate Professor of Medicine at the Myeloma Institute for Research and Therapy at UAMS and joined the department in 2014. She completed her fellowship in Hematology/Oncology in 2013 at Montefiore Medical Center in New York and performed a research fellowship in molecular and translational science at Einstein, New York in 2014 . She earned her medical degree at the University of Halle in Germany and completed her residency at the Jacobi Medical Center in New York in 2010. Dr. Schinke has several publications and scientific poster presentations/abstracts and is a member of the American Society of Hematology, American Society of Oncology and International Myeloma Society. Her clinical interests are plasma cell dyscrasias, including MGUS, smoldering multiple myeloma, plasma cell leukemia as well as amyloid disease and Waldenstroms.

Metrics

h-index: 36
Publications: 369
Citations: 4,773

Selected Publications

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025) DOI
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study (2025) DOI
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial (2024) DOI
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024) DOI
Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers (2024) DOI
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma (2024) DOI
Deciphering the genetics and mechanisms of predisposition to multiple myeloma (2024) DOI
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2024) DOI
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study (2024) DOI
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024) DOI
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023) DOI

Grants & Funding

No FP attached UAMS Intramural Grant (CTSA) Principal Investigator
No FP attached UAMS Intramural Grant (CTSA) Principal Investigator
MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma Pfizer, Inc. - Pass Through: ICON Clinical Research Principal Investigator
MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma Pfizer, Inc. - Pass Through: ICON Clinical Research Principal Investigator
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Pfizer, Inc. Principal Investigator
Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
RC Pilot Award UAMS College of Medicine Principal Investigator
RC Pilot Award UAMS College of Medicine Principal Investigator